A proprietary manufacturing process for peptide drugs

rBIO has developed a proprietary process and IP platform designed to increase manufacturing output for insulin and other peptide drugs, creating a path toward process-ready licensing.

How our platform creates value

rBIO’s platform combines proprietary process IP, manufacturing know-how, and process-development work to improve output for peptide-drug production.

The initial focus is insulin. rBIO’s objective is to complete scale-up, validate the process at commercial scale, and license the process to qualified partners.

The platform is designed to be:

  • Insulin-first

  • Output-focused

  • Built for scale-up

  • Intended for licensing

  • Expandable to additional peptide drugs over time

Roadmap

rBIO has completed early development work and is preparing for the next stage of process scale-up.

Current development path:

  • 20L Pilot — completed ☑️

  • Exploratory Animal Safety and Efficacy Study — completed ☑️

  • 1,000L Scale-Up — next planned milestone

  • Production Ready — target milestone

Our goal is to become process-ready to license.

Platform highlights

Proprietary process IP

rBIO’s platform combines manufacturing process know-how and proprietary IP designed to improve peptide-drug production output.

Output advantage

The process is designed to double the rate of insulin production compared to current industry production.

Scale-up path

rBIO has completed 20L pilot work and is preparing for 1,000L scale-up

Licensing model

The platform is being developed for licensing to qualified drug manufacturers, regional partners, CDMOs, distributors, and strategic pharma organizations.

Built for licensing and scale

rBIO’s strategy is to complete the process-development work needed to become license-ready, then support partners in regional and global markets.

This model is intended to reduce execution risk compared with building a fully owned manufacturing footprint from the start.

Partner with rBIO

With a home base in Houston, Texas, rBIO is located at a US epicenter of innovation in healthcare and biotechnology.

rBIO is engaging prospective investors, licensing partners, drug manufacturers, CDMOs, distributors, and strategic pharma organizations interested in more efficient peptide-drug manufacturing.